Hector F. Deluca

Biography

Hector F. DeLuca, is a co-founder of Deltanoid Pharmaceuticals, Inc. and is recognized as a world leader in vitamin D chemistry, biochemistry and medicine, and has nearly 820 filed and active patents on his technologies. The majority of commercially-developed vitamin D analogs have originated in Professor DeLuca’s university lab. Prior to establishing Deltanoid, Dr. DeLuca was involved in the development of eight drugs marketed worldwide with over $10 billion in worldwide sales, including Alfarol®, Zemplar®, Rocaltrol®, Hectorol® and several others. Dr. DeLuca has been a successful entrepreneur involved in the creation of the publicly held pharmaceutical firm Bone Care International (NASDAQ:BCII) that was later acquired by Genzyme/Sanofi. He also was a founder of Tetrionics, sold to SAFC. He also serves on the board of Kegonsa Capital Partners. Because of his expertise in the field of vitamin D, Dr. DeLuca has developed contacts with many major pharmaceutical companies world-wide, and has served as a consultant to many firms. Professor DeLuca was a faculty member in the Department of Biochemistry for over 50 years, and served for 30 years as Chairman of that department. He continues to maintain an active research program as an Emeritus Professor. He received his PhD in biochemistry from the University of Wisconsin-Madison, and honorary degrees of medicine from the University of Colorado, the Medical College of Wisconsin, the Karolinska Institute, Stockholm, and Queen’s University of Canada

Research Interest

His research interests include fields like Pharmaceuticals